A
Angelo Branzi
Researcher at University of Bologna
Publications - 350
Citations - 17546
Angelo Branzi is an academic researcher from University of Bologna. The author has contributed to research in topics: Atrial fibrillation & Heart failure. The author has an hindex of 58, co-authored 350 publications receiving 16425 citations.
Papers
More filters
Diagnosis of idiopathic restrictive cardiomyopathy at a glance.J Cardiovasc Med (Hagerstown). 2007 Sep;8(9):758. No abstract available.
Elena Biagini,Ornella Leone,Francesco Grigioni,Marinella Ferlito,Angelo Branzi,Claudio Rapezzi +5 more
TL;DR: In this article, a 41-year-old woman was referred for pretransplantation screening following a long history of congestive heart failure, and the main physical findings were bilateral leg oedema, hepatomegaly, raised jugular venous pressure and third heart sound.
Journal Article
TROMBOLISI PER VIA VENOSA MEDIANTE L'ATTIVATORE TISSUTALE UMANO RICOMBINANTE DEL PLASMINOGENO (rt-PA) NELLE PRIME TRE ORE DELL'INFARTO MIOCARDICO ACUTO. STUDIO PILOTA CONTROLLATO CON PLACEBO
Giovanni Melandri,Angelo Branzi,Berardi C,Bruscoli F,Tartagni F,Binetti G,Nazzareno Galiè,Bruno Magnani,G.F. Gensini,R. Abbate,D. Prisco,G. G. Neri serneri +11 more
Journal ArticleDOI
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope
TL;DR: In selected patients with malignant vasovagal syncope, treatment with metaprolol or propranolol at relatively high doses is feasible and, if guided by HUT results, is associated with a favorable outcome in terms of freedom from syncopal recurrences.
Journal ArticleDOI
Clinical use of novel antithrombotic agents in the management of acute coronary syndromes.
Giovanni Melandri,Pierluigi Tricoci,Chiara Melloni,Samuele Nanni,Franco Semprini,Francesco Fallani,Angelo Branzi +6 more
TL;DR: Among patients with ST elevation-acute coronary syndrome (ACS) novel thrombolytic agents can be given as a bolus (reteplase, tenecteplase) and their delivery is easier and may shorten the time to treatment, providing the ideal tool in the pre-hospital setting.
Journal ArticleDOI
Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation
Francesco Grigioni,Antonio Russo,Luciano Potena,Alfonso Ielasi,F. Fabbri,Letizia Bacchi-Reggiani,Samuela Carigi,Anna Chiara Musuraca,Mauro Bigliardi,Fabio Coccolo,Gaia Magnani,Salvatore Specchia,Carlo Magelli,Angelo Branzi +13 more
TL;DR: CHF patients with intermediate peak VO(2) who display "stable" CHF present a lower incidence of adverse cardiac events, particularly in the absence of hypotension, severe mitral regurgitation, and severe reduction of LVEF.